Recombinant Sendai Virus Vectors as Novel Vaccine Candidates Against Animal Viruses
Viruses · 2025-05-21 · 17 (5) · 737
DOI: 10.3390/v17050737 ↗At a glance
Übersichtsarbeit in Viruses, published online on 2025-05-21. Written by Álex Gómez and 1 co-authors. Institution: Departamento de Patología Animal, Universidad de Zaragoza, 177 Calle de Miguel Sevet, 50013 Zaragoza, Spain. Major MEDLINE topics: Sendai virus, Viral Vaccines, Genetic Vectors, Virus Diseases. Cited 6 times so far (Crossref); 129 references. The full text is freely available (open access, CC BY 4.0). Funded by: Gobierno de Navarra.
Abstract (original language)
Vaccination plays a pivotal role in the control and prevention of animal infectious diseases. However, no efficient and safe universal vaccines are currently registered for major pathogens such as influenza A virus, foot-and-mouth disease virus (FMDV), simian immunodeficiency virus (SIV), and small ruminant lentiviruses (SRLV). Here, we review the development of Sendai virus (SeV) vectors as a promising vaccine platform for animal diseases. Recombinant SeV vectors (rSeVv) possess several key features that make them highly suitable for developing vaccination strategies: (1) SeV has exclusively cytoplasmic replication cycle, therefore incapable of transforming host cells by integrating into the cellular genome, (2) rSeVv can accommodate large foreign gene/s inserts (~5 kb) with strong but adjustable transgene expression, (3) can be propagated to high titers in both embryonated chicken eggs and mammalian cell lines, (4) exhibits potent infectivity across a broad range of mammalian cells from different animals species, (5) undergo transient replication in the upper and lower respiratory tracts of non-natural hosts, (6) has not been associated with disease in pigs, non-humans primates, and small ruminants, ensuring a favorable safety profile, and (7) induce a robust innate and cellular immune responses. Preclinical and clinical studies using rSeVv-based vaccines against influenza A virus, FMDV, SIV, and SRLV have yielded promising results. Therefore, this review highlights the potential of rSeVv-based vaccine platforms as a valuable strategy for combating animal viruses.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Departamento de Patología Animal, Universidad de Zaragoza, 177 Calle de Miguel Sevet, 50013 Zaragoza, Spain.
- Instituto Agroalimentario de Aragón-IA2, Universidad de Zaragoza, 177 Calle de Miguel Sevet, 50013 Zaragoza, Spain.
- Instituto de Agrobiotecnología (CSIC-Gobierno de Navarra), 123 Avenida Pamplona, 31192 Mutilva, Spain.
ORCID profiles: Álex Gómez, Ramsés Reina
Funding
- Gobierno de Navarra
Cite
APA
Gómez, Á., & Reina, R. (2025). Recombinant Sendai Virus Vectors as Novel Vaccine Candidates Against Animal Viruses. Viruses, 17(5), 737. https://doi.org/10.3390/v17050737
Vancouver
Gómez Á, Reina R. Recombinant Sendai Virus Vectors as Novel Vaccine Candidates Against Animal Viruses. Viruses. 2025;17(5):737. doi:10.3390/v17050737
BibTeX
@article{Gmez2025,
author = {Gómez, Álex and Reina, Ramsés},
title = {Recombinant Sendai Virus Vectors as Novel Vaccine Candidates Against Animal Viruses},
journal = {Viruses},
year = {2025},
volume = {17},
number = {5},
pages = {737},
doi = {10.3390/v17050737}
}
EUVIMED